Medical - Care Facilities
Build Your Comparison
Side-by-side financial analysisStock Comparison
TOI vs ADUS vs OPCH vs HCSG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
TOI vs ADUS vs OPCH vs HCSG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $5.41B | $1.74B | $3.25B | $1.60B |
| Revenue (TTM) | $546M | $1.45B | $5.67B | $1.84B |
| Net Income (TTM) | $-44M | $100M | $206M | $59M |
| Gross Margin | 14.8% | 32.5% | 18.0% | 13.3% |
| Operating Margin | -6.0% | 9.8% | 5.9% | 3.0% |
| Forward P/E | — | 13.3x | 11.3x | 20.7x |
| Total Debt | $104M | $209M | $0.00 | $25M |
| Cash & Equiv. | $34M | $82M | $233M | $161M |
TOI vs ADUS vs OPCH vs HCSG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| The Oncology Instit… (TOI) | 100 | 52.8 | -47.2% |
| Addus HomeCare Corp… (ADUS) | 100 | 100.8 | +0.8% |
| Option Care Health,… (OPCH) | 100 | 149.6 | +49.6% |
| Healthcare Services… (HCSG) | 100 | 91.5 | -8.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TOI vs ADUS vs OPCH vs HCSG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TOI has the current edge in this matchup, primarily because of its strength in growth exposure.
- Rev growth 27.8%, EPS growth 23.9%, 3Y rev CAGR 25.8%
- 27.8% revenue growth vs HCSG's 7.1%
- +100.4% vs OPCH's -34.9%
ADUS is the clearest fit if your priority is long-term compounding and defensive.
- 369.2% 10Y total return vs OPCH's 127.6%
- Beta 0.43, current ratio 1.80x
- 6.9% margin vs TOI's -8.0%
OPCH is the #2 pick in this set and the best alternative if value and stability is your priority.
- Lower P/E (11.3x vs 13.3x)
- Beta 0.29 vs TOI's 1.95
HCSG is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 19 yrs, beta 1.12
- Lower volatility, beta 1.12, Low D/E 4.8%, current ratio 3.38x
- 7.3% ROA vs TOI's -26.5%, ROIC 9.0% vs -41.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.8% revenue growth vs HCSG's 7.1% | |
| Value | Lower P/E (11.3x vs 13.3x) | |
| Quality / Margins | 6.9% margin vs TOI's -8.0% | |
| Stability / Safety | Beta 0.29 vs TOI's 1.95 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +100.4% vs OPCH's -34.9% | |
| Efficiency (ROA) | 7.3% ROA vs TOI's -26.5%, ROIC 9.0% vs -41.2% |
TOI vs ADUS vs OPCH vs HCSG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
TOI vs ADUS vs OPCH vs HCSG — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
OPCH leads in 2 of 6 categories
ADUS leads 1 • TOI leads 1 • HCSG leads 1 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ADUS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
OPCH is the larger business by revenue, generating $5.7B annually — 10.4x TOI's $546M. ADUS is the more profitable business, keeping 6.9% of every revenue dollar as net income compared to TOI's -8.0%. On growth, TOI holds the edge at +41.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $546M | $1.4B | $5.7B | $1.8B |
| EBITDAEarnings before interest/tax | -$26M | $159M | $406M | $72M |
| Net IncomeAfter-tax profit | -$44M | $100M | $206M | $59M |
| Free Cash FlowCash after capex | -$26M | $137M | $244M | $139M |
| Gross MarginGross profit ÷ Revenue | +14.8% | +32.5% | +18.0% | +13.3% |
| Operating MarginEBIT ÷ Revenue | -6.0% | +9.8% | +5.9% | +3.0% |
| Net MarginNet income ÷ Revenue | -8.0% | +6.9% | +3.6% | +3.2% |
| FCF MarginFCF ÷ Revenue | -4.7% | +9.5% | +4.3% | +7.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +41.2% | +7.7% | +1.3% | +6.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +90.5% | +17.2% | +3.6% | +175.0% |
Valuation Metrics
OPCH leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 16.3x trailing earnings, OPCH trades at a 41% valuation discount to HCSG's 27.6x P/E. On an enterprise value basis, OPCH's 7.4x EV/EBITDA is more attractive than HCSG's 22.5x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $5.4B | $1.7B | $3.2B | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $5.5B | $1.9B | $3.0B | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | -9.83x | 17.90x | 16.35x | 27.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 13.35x | 11.31x | 20.67x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.89x | — | — |
| EV / EBITDAEnterprise value multiple | — | 12.04x | 7.38x | 22.45x |
| Price / SalesMarket cap ÷ Revenue | 10.75x | 1.22x | 0.57x | 0.87x |
| Price / BookPrice ÷ Book value/share | — | 1.59x | 2.56x | 3.20x |
| Price / FCFMarket cap ÷ FCF | — | 16.76x | 12.57x | 11.52x |
Profitability & Efficiency
OPCH leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
OPCH delivers a 15.3% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $9 for ADUS. HCSG carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to ADUS's 0.19x. On the Piotroski fundamental quality scale (0–9), ADUS scores 7/9 vs TOI's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +9.3% | +15.3% | +11.8% |
| ROA (TTM)Return on assets | -26.5% | +7.0% | +6.0% | +7.3% |
| ROICReturn on invested capital | -41.2% | +8.8% | +15.3% | +9.0% |
| ROCEReturn on capital employed | -33.7% | +10.9% | +12.8% | +7.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 | 5 | 7 |
| Debt / EquityFinancial leverage | — | 0.19x | — | 0.05x |
| Net DebtTotal debt minus cash | $70M | $127M | -$233M | -$136M |
| Cash & Equiv.Liquid assets | $34M | $82M | $233M | $161M |
| Total DebtShort + long-term debt | $104M | $209M | $0 | $25M |
| Interest CoverageEBIT ÷ Interest expense | -4.96x | 14.45x | 5.50x | 33.02x |
Total Returns (Dividends Reinvested)
TOI leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ADUS five years ago would be worth $10,265 today (with dividends reinvested), compared to $5,257 for TOI. Over the past 12 months, TOI leads with a +100.4% total return vs OPCH's -34.9%. The 3-year compound annual growth rate (CAGR) favors TOI at 111.1% vs OPCH's -11.6% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +44.7% | -12.5% | -35.6% | +29.0% |
| 1-Year ReturnPast 12 months | +100.4% | -18.2% | -34.9% | +51.0% |
| 3-Year ReturnCumulative with dividends | +841.3% | +0.5% | -30.9% | +55.4% |
| 5-Year ReturnCumulative with dividends | -47.4% | +2.7% | +1.1% | -24.9% |
| 10-Year ReturnCumulative with dividends | -45.3% | +369.2% | +127.6% | -30.2% |
| CAGR (3Y)Annualised 3-year return | +111.1% | +0.2% | -11.6% | +15.8% |
Risk & Volatility
Evenly matched — TOI and OPCH each lead in 1 of 2 comparable metrics.
Risk & Volatility
OPCH is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than TOI's 1.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TOI currently trades 95.2% from its 52-week high vs OPCH's 56.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.95x | 0.43x | 0.29x | 1.12x |
| 52-Week HighHighest price in past year | $5.58 | $124.44 | $36.80 | $24.39 |
| 52-Week LowLowest price in past year | $2.02 | $87.95 | $18.01 | $12.66 |
| % of 52W HighCurrent price vs 52-week peak | +95.2% | +75.0% | +56.4% | +91.7% |
| RSI (14)Momentum oscillator 0–100 | 65.3 | 49.9 | 44.1 | 59.0 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 231K | 3.2M | 646K |
Analyst Outlook
HCSG leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: TOI as "Buy", ADUS as "Buy", OPCH as "Buy", HCSG as "Hold". Consensus price targets imply 50.7% upside for TOI (target: $8) vs 9.5% for HCSG (target: $25).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $8.00 | $122.00 | $31.22 | $24.50 |
| # AnalystsCovering analysts | 5 | 16 | 14 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 2 | 1 | 19 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +9.5% | +3.8% |
OPCH leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). ADUS leads in 1 (Income & Cash Flow). 1 tied.
TOI vs ADUS vs OPCH vs HCSG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is TOI or ADUS or OPCH or HCSG a better buy right now?
For growth investors, The Oncology Institute, Inc.
(TOI) is the stronger pick with 27. 8% revenue growth year-over-year, versus 7. 1% for Healthcare Services Group, Inc. (HCSG). Option Care Health, Inc. (OPCH) offers the better valuation at 16. 3x trailing P/E (11. 3x forward), making it the more compelling value choice. Analysts rate The Oncology Institute, Inc. (TOI) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — TOI or ADUS or OPCH or HCSG?
On trailing P/E, Option Care Health, Inc.
(OPCH) is the cheapest at 16. 3x versus Healthcare Services Group, Inc. at 27. 6x. On forward P/E, Option Care Health, Inc. is actually cheaper at 11. 3x.
03Which is the better long-term investment — TOI or ADUS or OPCH or HCSG?
Over the past 5 years, Addus HomeCare Corporation (ADUS) delivered a total return of +2.
7%, compared to -47. 4% for The Oncology Institute, Inc. (TOI). Over 10 years, the gap is even starker: ADUS returned +369. 2% versus TOI's -45. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — TOI or ADUS or OPCH or HCSG?
By beta (market sensitivity over 5 years), Option Care Health, Inc.
(OPCH) is the lower-risk stock at 0. 29β versus The Oncology Institute, Inc. 's 1. 95β — meaning TOI is approximately 580% more volatile than OPCH relative to the S&P 500. On balance sheet safety, Healthcare Services Group, Inc. (HCSG) carries a lower debt/equity ratio of 5% versus 19% for Addus HomeCare Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — TOI or ADUS or OPCH or HCSG?
By revenue growth (latest reported year), The Oncology Institute, Inc.
(TOI) is pulling ahead at 27. 8% versus 7. 1% for Healthcare Services Group, Inc. (HCSG). On earnings-per-share growth, the picture is similar: Healthcare Services Group, Inc. grew EPS 52. 8% year-over-year, compared to 3. 3% for Option Care Health, Inc.. Over a 3-year CAGR, TOI leads at 25. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — TOI or ADUS or OPCH or HCSG?
Addus HomeCare Corporation (ADUS) is the more profitable company, earning 6.
7% net margin versus -12. 1% for The Oncology Institute, Inc. — meaning it keeps 6. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADUS leads at 9. 7% versus -7. 2% for TOI. At the gross margin level — before operating expenses — ADUS leads at 32. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is TOI or ADUS or OPCH or HCSG more undervalued right now?
On forward earnings alone, Option Care Health, Inc.
(OPCH) trades at 11. 3x forward P/E versus 20. 7x for Healthcare Services Group, Inc. — 9. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TOI: 50. 7% to $8. 00.
08Which pays a better dividend — TOI or ADUS or OPCH or HCSG?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is TOI or ADUS or OPCH or HCSG better for a retirement portfolio?
For long-horizon retirement investors, Addus HomeCare Corporation (ADUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
43), +369. 2% 10Y return). The Oncology Institute, Inc. (TOI) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ADUS: +369. 2%, TOI: -45. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between TOI and ADUS and OPCH and HCSG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TOI is a small-cap high-growth stock; ADUS is a small-cap high-growth stock; OPCH is a small-cap deep-value stock; HCSG is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.